Cardiovascular risk of Janus kinase inhibitors compared with biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis without underlying cardiovascular diseases: a nationwide cohort study

Cardiovascular risk of Janus kinase inhibitors compared with biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis without underlying cardiovascular diseases: a nationwide cohort study

Objectives: Despite the ethnic differences in cardiovascular (CV) risks and recent increase in the prescription of Janus kinase (JAK) inhibitors, limited evidence is available for their CV outcomes in Asian patients with rheumatoid arthritis (RA). We aimed to compare the major adverse CV events (MAC...

Full description

Bibliographic Details
Main Authors: Yun-Kyoung Song, Gaeun Lee, Jinseub Hwang, Ji-Won Kim, Jin-Won Kwon
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-10-01
Series:Frontiers in Pharmacology
Subjects:
janus kinase inhibitors
biologic DMARDs
cardiovascular risk
asian
rheumatoid arthritis
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2023.1165711/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2023.1165711/full

Similar Items